Involvement of cyclic guanosine monophosphate-dependent protein kinase I in renal antifibrotic effects of serelaxin

Frontiers in Pharmacology

Volumn 7, Issue JUL, 2016, Pages

  Wetzl, Veronika ^a,b   Schinner, Elisabeth ^a   Kees, Frieder ^a   Hofmann, Franz ^c   Faerber, Lothar ^a,b   Schlossmann, Jens ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

^b NOVARTIS PHARMA GMBH   (Germany)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

cGMP dependent protein kinase; Interstitial fibrosis; Kidney; Nitric oxide; Relaxin; Serelaxin; Signaling

Indexed keywords

COLLAGEN; COLLAGEN TYPE 1; COLLAGEN TYPE 1A1; CONNECTIVE TISSUE GROWTH FACTOR; CYCLIC GMP DEPENDENT PROTEIN KINASE 1; FIBRONECTIN; GELATINASE A; GELATINASE B; MITOGEN ACTIVATED PROTEIN KINASE 3; PHOSPHODIESTERASE 5A; PHOSPHODIESTERASE V; SERELAXIN; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIFIBROTIC ACTIVITY; ARTICLE; CELL DIFFERENTIATION; CONTROLLED STUDY; DRUG ACTIVITY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; KIDNEY FIBROSIS; MOUSE; MYOFIBROBLAST; NONHUMAN; SIGNAL TRANSDUCTION; URETER OBSTRUCTION;

EID: 84981333747     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2016.00195     Document Type: Article

References (60)

1. Abreu, J. G., Ketpura, N. I., Reversade, B., and De Robertis, E. M. (2002). Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta. Nat. Cell Biol. 4, 599-604.
2. Bae, E. H., Kim, I. J., Joo, S. Y., Kim, E. Y., Kim, C. S., Choi, J. S., et al. (2012). Renoprotective effects of sildenafil in DOCA-salt hypertensive rats. Kidney Blood Press. Res. 36, 248-257. doi: 10.1159/000343414
3. Bathgate, R. A., Halls, M. L., Van Der Westhuizen, E. T., Callander, G. E., Kocan, M., and Summers, R. J. (2013). Relaxin family peptides and their receptors. Physiol. Rev. 93, 405-480. doi: 10.1152/physrev.00001.2012
4. Beyer, C., Zenzmaier, C., Palumbo-Zerr, K., Mancuso, R., Distler, A., Dees, C., et al. (2015). Stimulation of the soluble guanylate cyclase (sGC) inhibits fibrosis by blocking non-canonical TGFbeta signalling. Ann. Rheum. Dis. 74, 1408-1416. doi: 10.1136/annrheumdis-2013-204508
5. Chevalier, R. L., Forbes, M. S., and Thornhill, B. A. (2009). Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int. 75, 1145-1152. doi: 10.1038/ki.2009.86
6. Chow, B. S., Chew, E. G., Zhao, C., Bathgate, R. A., Hewitson, T. D., and Samuel, C. S. (2012). Relaxin signals through a RXFP1-pERK-nNOS-NO-cGMP-dependent pathway to up-regulate matrix metalloproteinases: the additional involvement of iNOS. PLoS.ONE. 7:e42714. doi: 10.1371/journal.pone.0042714
7. Chow, B. S., Kocan, M., Bosnyak, S., Sarwar, M., Wigg, B., Jones, E. S., et al. (2014). Relaxin requires the angiotensin II type 2 receptor to abrogate renal interstitial fibrosis. Kidney Int. 86, 75-85. doi: 10.1038/ki.2013.518
8. Cole, R. T., Masoumi, A., Triposkiadis, F., Giamouzis, G., Georgiopoulou, V., Kalogeropoulos, A., et al. (2012). Renal dysfunction in heart failure. Med. Clin. North Am. 96, 955-974. doi: 10.1016/j.mcna.2012.07.005
9. Cui, W., Maimaitiyiming, H., Qi, X., Norman, H., Zhou, Q., Wang, X., et al. (2014). Increasing cGMP-dependent protein kinase activity attenuates unilateral ureteral obstruction-induced renal fibrosis. Am. J. Physiol. Renal Physiol. 306, F996-F1007. doi: 10.1152/ajprenal.00657.2013
10. Danielson, L. A., Welford, A., and Harris, A. (2006). Relaxin improves renal function and histology in aging Munich Wistar rats. J. Am. Soc. Nephrol. 17, 1325-1333. doi: 10.1681/ASN.2005121307
11. Francis, S. H., Busch, J. L., Corbin, J. D., and Sibley, D. (2010). cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action. Pharmacol. Rev. 62, 525-563. doi: 10.1124/pr.110.002907
12. Garber, S. L., Mirochnik, Y., Brecklin, C., Slobodskoy, L., Arruda, J. A., and Dunea, G. (2003). Effect of relaxin in two models of renal mass reduction. Am. J. Nephrol. 23, 8-12. doi: 10.1159/000066302
13. Garber, S. L., Mirochnik, Y., Brecklin, C. S., Unemori, E. N., Singh, A. K., Slobodskoy, L., et al. (2001). Relaxin decreases renal interstitial fibrosis and slows progression of renal disease. Kidney Int. 59, 876-882. doi: 10.1046/j.1523-1755.2001.059003876.x
14. Gonzalez-Avila, G., Iturria, C., Vadillo-Ortega, F., Ovalle, C., and Montano, M. (1998). Changes in matrix metalloproteinases during the evolution of interstitial renal fibrosis in a rat experimental model. Pathobiology 66, 196-204. doi: 10.1159/000028023
15. Halls, M. L., Bathgate, R. A., Sutton, S. W., Dschietzig, T. B., and Summers, R. J. (2015). International union of basic and clinical pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides. Pharmacol. Rev. 67, 389-440.
16. Heeg, M. H., Koziolek, M. J., Vasko, R., Schaefer, L., Sharma, K., Muller, G. A., et al. (2005). The antifibrotic effects of relaxin in human renal fibroblasts are mediated in part by inhibition of the Smad2 pathway. Kidney Int. 68, 96-109. doi: 10.1111/j.1523-1755.2005.00384.x
17. Hewitson, T. D., Ho, W. Y., and Samuel, C. S. (2010). Antifibrotic properties of relaxin: in vivo mechanism of action in experimental renal tubulointerstitial fibrosis. Endocrinology 151, 4938-4948. doi: 10.1210/en.2010-0286
18. Hewitson, T. D., Mookerjee, I., Masterson, R., Zhao, C., Tregear, G. W., Becker, G. J., et al. (2007). Endogenous relaxin is a naturally occurring modulator of experimental renal tubulointerstitial fibrosis. Endocrinology 148, 660-669. doi: 10.1210/en.2006-0814
19. Hisaw, F. L. (1929). The corpus luteum hormone. I. Experimental relaxation of the pelvic ligaments of the guinea pig. Physiol. Zool. 2, 59-79.
20. Honma, S., Shinohara, M., Takahashi, N., Nakamura, K., Hamano, S., Mitazaki, S., et al. (2014). Effect of cyclooxygenase (COX)-2 inhibition on mouse renal interstitial fibrosis. Eur. J. Pharmacol. 740, 578-583. doi: 10.1016/j.ejphar.2014.06.027
21. Hsu, S. Y., Nakabayashi, K., Nishi, S., Kumagai, J., Kudo, M., Sherwood, O. D., et al. (2002). Activation of orphan receptors by the hormone relaxin. Science 295, 671-674. doi: 10.1126/science.1065654
22. Inoki, K., Haneda, M., Ishida, T., Mori, H., Maeda, S., Koya, D., et al. (2000). Role of mitogen-activated protein kinases as downstream effectors of transforming growth factor-beta in mesangial cells. Kidney Int. Suppl. 77, S76-S80. doi: 10.1046/j.1523-1755.2000.07712.x
23. Leask, A., and Abraham, D. J. (2004). TGF-beta signaling and the fibrotic response. FASEB J. 18, 816-827. doi: 10.1096/fj.03-1273rev
24. Lee, S. Y., Kim, S. I., and Choi, M. E. (2015). Therapeutic targets for treating fibrotic kidney diseases. Transl. Res. 165, 512-530. doi: 10.1016/j.trsl.2014.07.010
25. Lekgabe, E. D., Kiriazis, H., Zhao, C., Xu, Q., Moore, X. L., Su, Y., et al. (2005). Relaxin reverses cardiac and renal fibrosis in spontaneously hypertensive rats. Hypertension 46, 412-418. doi: 10.1161/01.HYP.0000171930.00697.2f
26. Lopez-De Leon, A., and Rojkind, M. (1985). A simple micromethod for collagen and total protein determination in formalin-fixed paraffin-embedded sections. J. Histochem. Cytochem. 33, 737-743. doi: 10.1177/33.8.2410480
27. Lowry, O. H., Rosebrough, N. J., Farr, A. L., and Randall, R. J. (1951). Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193, 265-275.
28. Masaki, T., Foti, R., Hill, P. A., Ikezumi, Y., Atkins, R. C., and Nikolic-Paterson, D. J. (2003). Activation of the ERK pathway precedes tubular proliferation in the obstructed rat kidney. Kidney Int. 63, 1256-1264. doi: 10.1046/j.1523-1755.2003.00874.x
29. Massague, J. (1998). TGF-beta signal transduction. Annu. Rev. Biochem. 67, 753-791. doi: 10.1146/annurev.biochem.67.1.753
30. Masterson, R., Hewitson, T. D., Kelynack, K., Martic, M., Parry, L., Bathgate, R., et al. (2004). Relaxin down-regulates renal fibroblast function and promotes matrix remodelling in vitro. Nephrol. Dial. Transplant. 19, 544-552. doi: 10.1093/ndt/gfg598
31. McDonald, G. A., Sarkar, P., Rennke, H., Unemori, E., Kalluri, R., and Sukhatme, V. P. (2003). Relaxin increases ubiquitin-dependent degradation of fibronectin in vitro and ameliorates renal fibrosis in vivo. Am. J. Physiol. Renal Physiol. 285, F59-F67. doi: 10.1152/ajprenal.00157.2002
32. McGuane, J. T., Debrah, J. E., Sautina, L., Jarajapu, Y. P., Novak, J., Rubin, J. P., et al. (2011). Relaxin induces rapid dilation of rodent small renal and human subcutaneous arteries via PI3 kinase and nitric oxide. Endocrinology 152, 2786-2796. doi: 10.1210/en.2010-1126
33. Metra, M., Cotter, G., Davison, B. A., Felker, G. M., Filippatos, G., Greenberg, B. H., et al. (2013). Effect of serelaxin on cardiac, renal, and hepatic biomarkers in the relaxin in acute heart failure (RELAX-AHF) development program: correlation With outcomes. J. Am. Coll. Cardiol. 61, 196-206. doi: 10.1016/j.jacc.2012.11.005
34. Mookerjee, I., Hewitson, T. D., Halls, M. L., Summers, R. J., Mathai, M. L., Bathgate, R. A., et al. (2009). Relaxin inhibits renal myofibroblast differentiation via RXFP1, the nitric oxide pathway, and Smad2. FASEB J. 23, 1219-1229. doi: 10.1096/fj.08-120857
35. Morisada, N., Nomura, M., Nishii, H., Furuno, Y., Sakanashi, M., Sabanai, K., et al. (2010). Complete disruption of all nitric oxide synthase genes causes markedly accelerated renal lesion formation following unilateral ureteral obstruction in mice in vivo. J. Pharmacol. Sci. 114, 379-389. doi: 10.1254/jphs.10143FP
36. Nagamoto, T., Eguchi, G., and Beebe, D. C. (2000). Alpha-smooth muscle actin expression in cultured lens epithelial cells. Invest. Ophthalmol. Vis. Sci. 41, 1122-1129.
37. Pat, B., Yang, T., Kong, C., Watters, D., Johnson, D. W., and Gobe, G. (2005). Activation of ERK in renal fibrosis after unilateral ureteral obstruction: modulation by antioxidants. Kidney Int. 67, 931-943. doi: 10.1111/j.1523-1755.2005.00157.x
38. Pfeifer, A., Klatt, P., Massberg, S., Ny, L., Sausbier, M., Hirneiss, C., et al. (1998). Defective smooth muscle regulation in cGMP kinase I-deficient mice. EMBO J. 17, 3045-3051. doi: 10.1093/emboj/17.11.3045
39. Piek, E., Ju, W. J., Heyer, J., Escalante-Alcalde, D., Stewart, C. L., Weinstein, M., et al. (2001). Functional characterization of transforming growth factor beta signaling in Smad2- and Smad3-deficient fibroblasts. J. Biol. Chem. 276, 19945-19953. doi: 10.1074/jbc.M102382200
40. Rodriguez-Iturbe, B., Ferrebuz, A., Vanegas, V., Quiroz, Y., Espinoza, F., Pons, H., et al. (2005). Early treatment with cGMP phosphodiesterase inhibitor ameliorates progression of renal damage. Kidney Int. 68, 2131-2142. doi: 10.1111/j.1523-1755.2005.00669.x
41. Ronco, P., Lelongt, B., Piedagnel, R., and Chatziantoniou, C. (2007). Matrix metalloproteinases in kidney disease progression and repair: a case of flipping the coin. Semin. Nephrol. 27, 352-362. doi: 10.1016/j.semnephrol.2007.02.006
42. Rybalkin, S. D., Rybalkina, I. G., Feil, R., Hofmann, F., and Beavo, J. A. (2002). Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation in smooth muscle cells. J. Biol. Chem. 277, 3310-3317. doi: 10.1074/jbc.M106562200
43. Samuel, C. S. (2005). Relaxin: antifibrotic properties and effects in models of disease. Clin. Med. Res. 3, 241-249. doi: 10.3121/cmr.3.4.241
44. Samuel, C. S., Zhao, C., Bathgate, R. A., Bond, C. P., Burton, M. D., Parry, L. J., et al. (2003). Relaxin deficiency in mice is associated with an age-related progression of pulmonary fibrosis. FASEB J. 17, 121-123.
45. Samuel, C. S., Zhao, C., Bond, C. P., Hewitson, T. D., Amento, E. P., and Summers, R. J. (2004). Relaxin-1-deficient mice develop an age-related progression of renal fibrosis. Kidney Int. 65, 2054-2064. doi: 10.1111/j.1523-1755.2004.00628.x
46. Schinner, E., Schramm, A., Kees, F., Hofmann, F., and Schlossmann, J. (2013). The cyclic GMP-dependent protein kinase Ialpha suppresses kidney fibrosis. Kidney Int. 84, 1198-1206. doi: 10.1038/ki.2013.219
47. Schinner, E., Wetzl, V., and Schlossmann, J. (2015). Cyclic nucleotide signalling in kidney fibrosis. Int. J. Mol. Sci. 16, 2320-2351. doi: 10.3390/ijms16022320
48. Schlossmann, J., and Schinner, E. (2012). cGMP becomes a drug target. Naunyn Schmiedebergs Arch Pharmacol. 385, 243-252. doi: 10.1007/s00210-012-0730-6
49. Schramm, A., Schinner, E., Huettner, J. P., Kees, F., Tauber, P., Hofmann, F., et al. (2014). Function of cGMP-dependent protein kinase II in volume load-induced diuresis. Pflugers Arch. 466, 2009-2018. doi: 10.1007/s00424-014-1445-y
50. Sharma, A. K., Mauer, S. M., Kim, Y., and Michael, A. F. (1995). Altered expression of matrix metalloproteinase-2, TIMP, and TIMP-2 in obstructive nephropathy. J. Lab. Clin. Med. 125, 754-761.
51. Sun, D., Wang, Y., Liu, C., Zhou, X., Li, X., and Xiao, A. (2012). Effects of nitric oxide on renal interstitial fibrosis in rats with unilateral ureteral obstruction. Life Sci. 90, 900-909. doi: 10.1016/j.lfs.2012.04.018
52. Suzuki, H., Uchida, K., Nitta, K., and Nihei, H. (2004). Role of mitogen-activated protein kinase in the regulation of transforming growth factor-beta-induced fibronectin accumulation in cultured renal interstitial fibroblasts. Clin. Exp. Nephrol. 8, 188-195. doi: 10.1007/s10157-004-0297-8
53. Teerlink, J. R., Cotter, G., Davison, B. A., Felker, G. M., Filippatos, G., Greenberg, B. H., et al. (2013). Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 381, 29-39. doi: 10.1016/S0140-6736(12)61855-8
54. Thomas, M. K., Francis, S. H., and Corbin, J. D. (1990). Substrate- and kinase-directed regulation of phosphorylation of a cGMP-binding phosphodiesterase by cGMP. J. Biol. Chem. 265, 14971-14978.
55. Wang, C., Kemp-Harper, B. K., Kocan, M., Ang, S. Y., Hewitson, T. D., and Samuel, C. S. (2016). The Anti-fibrotic actions of relaxin are mediated through a NO-sGC-cGMP-dependent pathway in renal myofibroblasts in vitro and enhanced by the NO Donor, diethylamine NONOate. Front. Pharmacol. 7:91. doi: 10.3389/fphar.2016.00091
56. Wang, Y., Kramer, S., Loof, T., Martini, S., Kron, S., Kawachi, H., et al. (2006). Enhancing cGMP in experimental progressive renal fibrosis: soluble guanylate cyclase stimulation vs. phosphodiesterase inhibition. Am. J. Physiol. Renal Physiol. 290, F167-F176. doi: 10.1152/ajprenal.00197.2005
57. Wang-Rosenke, Y., Mika, A., Khadzhynov, D., Loof, T., Neumayer, H.-H., and Peters, H. (2011). Stimulation of soluble guanylate cyclase improves renal recovery after relief of unilateral ureteral obstruction. J. Urol. 186, 1142-1149. doi: 10.1016/j.juro.2011.04.108
58. Yeh, J. L., Hsu, J. H., Wu, P. J., Liou, S. F., Liu, C. P., Chen, I. J., et al. (2010). KMUP-1 attenuates isoprenaline-induced cardiac hypertrophy in rats through NO/cGMP/PKG and ERK1/2/calcineurin A pathways. Br. J. Pharmacol. 159, 1151-1160. doi: 10.1111/j.1476-5381.2009.00587.x
59. Yokoi, H., Mukoyama, M., Nagae, T., Mori, K., Suganami, T., Sawai, K., et al. (2004). Reduction in connective tissue growth factor by antisense treatment ameliorates renal tubulointerstitial fibrosis. J. Am. Soc. Nephrol. 15, 1430-1440. doi: 10.1097/01.ASN.0000130565.69170.85
60. Zhang, Q. L., and Rothenbacher, D. (2008). Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 8:117. doi: 10.1186/1471-2458-8-117